Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model

Figure 3 Effect of erlotinib treatment on pathological analysis in an animal model of colitis-associated dysplasia. The percentage of animals with the most severe diagnosis found in each region of the colon is shown (^aP < 0.05, ^bP < 0.01 vs normal animals; ^dP < 0.05, ^eP < 0.01 vs vehicle-treated animals; n = 10-20 ± SE). MC: Methyl cellulose; NSI: Non-specific inflammation; IBD: Inflammatory bowel disease.